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Abstract
Background: The health impacts of pulmonary impairment after tuberculosis (TB) treatment have not been included 
in assessments of TB burden. Therefore, previous global and national TB burden estimates do not reflect the full 
consequences of surviving TB. We assessed the burden of TB including pulmonary impairment after tuberculosis in 
Tarrant County, Texas using Disability-adjusted Life Years (DALYs).
Methods: TB burden was calculated for all culture-confirmed TB patients treated at Tarrant County Public Health 
between January 2005 and December 2006 using identical methods and life tables as the Global Burden of Disease 
Study. Years of life-lost were calculated as the difference between life expectancy using standardized life tables and 
age-at-death from TB. Years lived-with-disability were calculated from age and gender-specific TB disease incidence 
using published disability weights. Non-fatal health impacts of TB were divided into years lived-with-disability-acute 
and years lived-with-disability-chronic. Years lived-with-disability-acute was defined as TB burden resulting from illness 
prior to completion of treatment including the burden from treatment-related side effects. Years lived-with-disability-
chronic was defined as TB burden from disability resulting from pulmonary impairment after tuberculosis.
Results: There were 224 TB cases in the time period, of these 177 were culture confirmed. These 177 subjects lost a 
total of 1189 DALYs. Of these 1189 DALYs 23% were from years of life-lost, 2% were from years lived-with-disability-
acute and 75% were from years lived-with-disability-chronic.
Conclusions: Our findings demonstrate that the disease burden from TB is greater than previously estimated. 
Pulmonary impairment after tuberculosis was responsible for the majority of the burden. These data demonstrate that 
successful TB control efforts may reduce the health burden more than previously recognized.
Background
Tuberculosis (TB) is an important cause of morbidity and
mortality worldwide. In 2003, an estimated 8.8 million
new TB cases and 1.7 million TB deaths were reported
globally [1,2]. The spread of HIV, a rise in TB drug resis-
tance, and the increase in global movement of persons
from high to low TB incidence areas have contributed to
the growing health threat due to TB [1-4]. Worldwide
there are an unknown but substantial number of patients
who have survived acute TB disease.
Pulmonary TB survivors frequently experience struc-
tural [5,6] and functional lung sequelae [7,8] that vary in
severity that have recently been more completely
described [8-10]. Measuring the negative health impacts
of these sequelae is an important component to deter-
mining the burden of TB, a disease in which control
efforts are largely publicly funded. The translation of
physical burden into a standard measure of health effect
is now possible and allows comparative analyses between
alternative uses of funding.
An accurate estimation of disease burden should
include all known negative health effects [3,4,11-
20,22,23]. This is especially true for TB in low-incidence
countries, where death from TB is rare and therefore the
TB disease burden may be underappreciated [2,14-
16,20,22,23]. The measurement of non-fatal, negative
health effects is important to fully estimate TB disease
burden [11-14]. Pulmonary impairment after tuberculo-
sis was recently described as a non-fatal negative health
* Correspondence: jotam.pasipanodya@UTSouthwestern.edu
2 Department of Medicine, University of North Texas Health Science Center at 
Fort Worth, Fort Worth, Texas, USA
Full list of author information is available at the end of the articlePasipanodya et al. BMC Public Health 2010, 10:259
http://www.biomedcentral.com/1471-2458/10/259
Page 2 of 10
effect [8-10]. Pulmonary impairment after TB was identi-
fied in more than half of microbiologically cured patients,
varied in severity with approximately 10% having lost
m o r e  t h a n  h a l f  o f  t h e i r  l u n g  f u n c t i o n  [ 8 ] .  P u l m o n a r y
impairment after tuberculosis has not been incorporated
in assessments of TB burden [2,14-16,20,22,23].
O n e  m e a n s  t o  d e s c r i b e  n e g a t i v e  h e a l t h  e f f e c t s  i s  b y
using disability adjusted life-years (DALYs). DALYs are
numerical values representing both the sum of years-of-
life-lost due to premature mortality and the years lived
with disability [13]. DALYs represent negative health
effects of disease in a population. One DALY represents
the loss of one year of equivalent, complete health. There-
fore, DALYs can measure gain or loss of population
health in a value that is comparable across different
resources used for prevention and control.
There are diverse methods for measuring non-fatal
health outcomes and as a consequence some evaluations
h a v e  c a l c u l a t e d  D A L Y s  i n  m a r k e d l y  d i f f e r e n t  w a y s
[14,15,19,20]. Prior estimates of DALYs lost from TB have
included only health lost from acute illness and death
[14-23]. As a result, the global [14] and U.S. national [15]
TB burden estimates do not fully reflect the conse-
quences of surviving TB disease. For practical and bench-
marking purposes, we used the Global Burden of Disease
Study methods on a defined population for a defined
period of time to recalculate the relative DALYs associ-
ated with the burden of TB but including pulmonary
impairment after tuberculosis in the estimate. In addition
we compared effects of using the local Texas life-tables in
place of the Japanese life tables commonly used in esti-
mating DALYs.
Methods
We analyzed data of culture-positive TB cases treated at
Tarrant County, Texas Public Health (TCPH) TB Elimi-
nation Division from January 2005 to December 2006,
including Tarrant County TB deaths reported during the
same period. TCPH serves approximately 1.7 million res-
idents in north central Texas [24]. By Texas statute all
persons with positive TB cultures must be reported to the
local health authority, and by policy of the Texas Depart-
m e n t of  S ta t e  H eal t h Se rvic es  a ll per sons  wit h T B a r e
treated with directly observed therapy (DOT) [25,26].
Overall TB Burden (DALY)
TB burden was calculated for 16 TB deaths and 161 cul-
ture-confirmed TB patients treated at TCPH between
January 2005 and December 2006 using identical meth-
ods and life tables as the Global Burden of Disease Study
by Murray et al [13,26]. Years-of-life-lost from premature
mortality (YLL) and Years-lived-with-disability (YLD)
were estimated with respect to a standard expectation of
life at each age using West 26 model life tables
[13,14,27,28]. We used a hypothetical norm of the maxi-
mum possible life expectancies for all ages to make
DALYs comparable across cultures, countries, and
regions [13,14]. With this assumption, Japanese life
expectancies at birth where females are expected to live
for 82.5 years were used [13,14,27,28] with a Texas life-
table used for comparison [29]. Clinical TB includes in
addition to culture negative tuberculosis diseases other
than tuberculosis. To improve precision of TB burden
estimates we excluded clinical TB from our calculations.
Disability data-Years lived with disability (YLD)
Non-fatal health impacts of TB were divided into years
lived with both acute (YLD-acute) and chronic disability
(YLD-chronic). Years lived-with-disability therefore com-
bines duration and severity of acute disease and disability
from sequelae. Years lived-with-disability-acute (YLD-
acute) was defined as TB burden resulting from illness
prior to completion of treatment and the burden from
treatment-related side effects. It included disability from
tuberculosis at diagnosis to end-of-treatment. The dura-
tion of YLD-acute was assumed to be 6-months [16-20].
YLD-acute was calculated by multiplying the duration of
acute disease by an age-weighted disability weight factor,
discounted at 3% per year [13,17,18,30]. Years lived-with-
disability-chronic (YLD-chronic) was defined as perma-
n e n t  T B  b u r d e n  f r o m  d i s a b i l i t y  r e s u l t i n g  f r o m  P I A T .
YLD-chronic was calculated by multiplying the estimated
remaining years of life after completion of therapy by age-
weighted disability weight factor, also discounted at 3%,
per year, for the duration of remaining years of life lived
with disability. Further details about DALY computation
assumptions are shown in the attached appendix.
Disability weight, a scaling factor that ranges from 0
(representing the best possible health state) to 1 (repre-
senting the worst possible living heath state; equated to
death), is an essential component of years lived with dis-
ability computation. The disability weights used were
obtained from prior reports of the Global Diseases Study
and the Dutch disability weighting study [14,16,18]. They
were 0.294 for ages 0-14, 0.264 for 15-59 and 0.274 for the
60+. We also derived disability weights stratified by
impairment levels from these TB survivors using the St
George's respiratory questionnaire and Spirometry [8,9].
The disability weights for non-impaired persons were
0.173. Those for mildly impaired was 0.248, moderately
impaired 0.273 and severely impaired 0.377 [9]. We tested
these locally derived disability weights in sensitivity anal-
ysis. Extra-pulmonary TB cases were excluded in estimat-
ing YLD-chronic estimates because there are no data to
support assumptions for burden from long-term sequale.Pasipanodya et al. BMC Public Health 2010, 10:259
http://www.biomedcentral.com/1471-2458/10/259
Page 3 of 10
Mortality data-Years of life lost (YLL)
Years of life-lost were calculated for each reported death
due to TB as the difference between life expectancy and
age-at-death. These differences were then summed across
the Tarrant County population using the identical meth-
ods and life tables as the Global Burden of Disease Study
[13,14]. Each death due to TB was attributed to a single
cause according to the International Classification of Dis-
ease (ICD) for attribution of causes of death [31]. Years-
of-life-lost was then computed using the formula YLL[r,
K, β] = KCera/(r+ β)2{e-(r+ β)(L+a)[-(r+ β)(L+a)-1]-e-(r+ β)a[-
(r+ β)a-1]}+(1-K)/r(1-e-rl) where K = age weighting mod-
ulation factor; C = Constant; r = discount rate; a = age of
death; β = parameter from the age weighting function;
and L = standard expectation of life at age-of-death
[13,14]. The value of C = 0.01458 together with β = 0.04
and K = 0 produce uniform age weighting when the dis-
count rate is zero. Discounting is the standard method
used to adjust the value of money, cost, and benefits to
reflect preference for present rather than future utility;
interest is paid on monetary loans for the same reason
[4,13-20].
Sensitivity Analysis
The Global Burden of Disease Study of 1996 methods and
assumptions were used to estimate Tarrant County data
that included disability due to pulmonary impairment
after tuberculosis. This base DALY calculation was made
for ease of comparison. Since years lived-with-disability-
acute contributed very little to total burden, it was not
included in sensitivity analysis. We assumed survivors of
TB treatment have a normal life expectancy [13,14,17].
Total DALYs were stratified by gender, age and race.
DALYs were not adjusted for co-morbidity. Mortality
included all TB deaths reported in T arrant County. The
base DALY [r, K, β] was; r = 0.03, K = 0 and β = 0.04. Prior
data suggests that estimates of TB burden should vary
based on severity of impairment resulting from TB dis-
ease, in addition to the age at which disease occurs [8],
[9], [13-20], Vecino ME, Pasipanodya JG, Slocum PC, Bae
S, Munguia G, Miller TL, Drewyer G, Weis SE. 2010]. Evi-
dence for chronic lung impairment in patients cured of
tuberculosis; Submitted]. Sensitivity analyses were per-
formed with varied discount rates, disability weights, age
weights, and local life tables [8,9,13,14,16,32]. Discount
rates varied from 0% to 10% and the disability weights
from 0.173 to 0.377 depending on disease severity. We
also used previously published data (figure sixteen.one
from reference 33) to test potential policy implications of
these data on TB interventions.
Parametric and non-parametric tests were performed
and reported unless otherwise stated. Data were analyzed
using SPSS version 12 for Windows (SPSS Inc. 233 S.
Wacker Dr, Chicago IL 60606-6307) and Microsoft Excel
2002 (Microsoft Corporation, Richmond, WA).
Results
Descriptive
There were 224 TB cases in Tarrant County, Texas,
between January 1, 2005 and December 31, 2006. Forty-
seven patients (22 females) were treated for clinical TB
and none of these died. Clinical TB was excluded from
further analysis henceforth. Of the remaining 177
patients with tuberculosis confirmed by culture or histol-
ogy 155 (88%) had pulmonary and 22 (12%) extra-pulmo-
n a ry  t u b e r c u l o s i s .  D u r i n g  t h i s  p e r i o d  1 6  ( 9 % )  p a t i e n t s
died and of these 14 had pulmonary and 2 had extra-pul-
monary TB. Male TB patients outnumbered female (123
[69%] vs. 54 [31%]). The median age in years of males
(interquartile range) was 47 (23) versus 39 (24) for
females. TB patients were racially heterogeneous with
Caucasians and Hispanics together comprising 50%,
while the HIV prevalence was 11% (table 1).
Overall TB burden - DALY
A total of 1189 DALYs were lost among these 177 TB
patients, with 274 DALYs lost from years-of-life-lost and
915 DALYs lost from acute and chronic years lived-with-
disability (table 2; figure 1). Males lost nearly 857 DALYs,
72% of the total (figure 1). DALY loss varied significantly
by age (p < 0.001): persons 30-44 years of age had a total
of 407 (34% of total) DALYs lost. Most (75%) of the
DALYs loss in the 30-44 age group were due to years
lived-with-disability-chronic. Years-of-life-lost accounted
for 23% of the DALYs lost (table 2). Among African-
American patients, 18% of the total DALYs lost was due
to years-of-life-lost in patients younger than 60 years of
age (table 2). Caucasians comprised 25% of the patient
population and contributed 25% of total DALYs lost. The
22 (12%) patients with extra-pulmonary TB lost only 39
DALYs (3% of total). The 16 TB deaths included 14 males
and 2 females; 4 Caucasians, 4 African-American, 3 His-
panics, 2 Asians and 1 African. The majority of years-of-
life-lost (70%) resulted from deaths in persons younger
than 60 years of age. US born persons contributed two
thirds of total years-of-life-lost (table 2).
There were differences in DALY loss and its sources
between Caucasians and other races (table 2; figure 2).
There was no tuberculosis or correspondent DALY loss
in Caucasian children under 5 years old. There was sub-
stantial DALY loss to young children in other ethnic
groups. Eleven percent of the DALY loss in Hispanics
occurred in children younger than 5 years (table 2). Three
percent of DALY loss in each of African-American and all
other races as a group occurred in children less than 5
years old. None of the DALY loss to Caucasians between
age 5 and 45 years was due to years-of-life-lost prematurePasipanodya et al. BMC Public Health 2010, 10:259
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mortality, but years-of-life-lost substantially contributed
to total DALY loss in non-Whites younger than 45 years.
Premature mortality in those under age 45 accounted for
31% (48.5/155.7) of DALYs lost to African-Americans,
11% (23.3/217.08) to Hispanics, and 14% (24/173.57) to
combined other races. Race was not a significant predic-
tor (p = 0.273) for total DALY when age was controlled
for; but was statistically significant (p = 0.028) in predict-
ing YLD-chronic (data not shown).
Disability data-Years lived with disability (YLD)
YLD comprised the majority (75%) of the TB burden.
YLD-acute contributed 23 (2%) of the total DALYs lost,
and YLD-chronic contributed 235 (73%) (table 2; figure
1). The mean YLD lost-per-patient for YLD-acute was
0.14 and for YLD-chronic was 5.04 DALYs. The overall
burden of TB was greater among males since more males
had and died with TB. However, the median value for
YLD-acute, YLD-chronic, and total DALY for men was
not significantly different from females (p-values 0.102,
0.066 and 0.575, respectively). YLD-chronic was greater
in foreign-born than US-born patients, as foreign-born
subjects were younger when they developed tuberculosis
(table 2).
Mortality data-Years of life lost (YLL)
The mean TB burden from years-of-life-lost was 1.55
DALYs per patient. The tuberculosis burden from years-
of-life-lost was greater in US than foreign-born persons
but did not reach statistical significance (2.27 vs. 1.10
DALYs) (table 2).
Sensitivity Analysis
We also analyzed the effects of varying the discount rates
(figure 2) and applying full age weights (data not shown).
Changes in the discount rate from 0% to 10% had little
effect (5% changes) on the distribution of burden by gen-
der, while a lower discount rate increased and clustered
the DALY burden at lower age groups (figure 3). Applying
full age weights lowered the total TB burden by 6% (figure
Table 1: Demographic characteristics of patients with culture confirmed tuberculosis between January 1, 2005 and 
December 31, 2006, Tarrant County, Texas.
Demographic Characteristic Male Female Total
N (%) N (%) N (%)
Mortality Status Alive 109 (89) 52 (96) 161 (91)
Dead 14 (11) 2 (4) 16 (9)
Disease Site Pulmonary 113 (92) 42 (78) 155 (88)
Extra-pulmonary 10 (8) 12 (22) 22 (12)
Age groups 0-4 2 (2) 5 (9) 7 (4)
5-14 0 0 0
15-29 17 (14) 10 (19) 27 (15)
30-44 33 (27) 20 (37) 53 (30)
45-59 43 (35) 11 (20) 54 (31)
60-69 15 (12) 4 (7) 19 (11)
70-79 10 (8) 3 (6) 13 (7)
80+ 3 (2) 1 (2) 4 (2)
Racial Groups Caucasian 33 (27) 11 (20) 44 (25)
Hispanic 32 (26) 13 (24) 45 (25)
African-American 31 (25) 10 (18) 41 (23)
Asians, Africans, Indians, Others 27 (22) 20 (37) 47 (27)
HIV# status Negative 99 (80) 47 (87) 146 (83)
Positive 17 (14) 3 (6) 20 (11)
Unknown 7 (6) 4 (7) 11 (6)
Country of Birth USA born 67 (55) 21 (39) 88 (50)
Foreign-born 56 (45) 33 (61) 89 (50)
Total 123 (100) 54 (100) 177 (100)
#HIV = Human Immunodeficiency VirusPasipanodya et al. BMC Public Health 2010, 10:259
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3). When we used disability weights that adjusted for
clinical severity of disease and were obtained from the
same patient population [9,10], total burden was 45%
lower compared to an analysis that used fixed disability
weights (data not shown).
When Texas life-tables were used to compute TB bur-
den, the overall TB was lower 1025 DALYs compared to
1189 DALYs when Japanese life-tables were used. Males
contributed 745 DALYs and females 280 DALYs. A uni-
f o r m  1 4 %  d i f f e r e n c e  i n  t u b e r c u l o s i s  b u r d e n  a p p l i c a b l e
across gender and age-groups was observed (figure 4).
Table 2: The mean and total TB burden of 161 survivors and 16 patients who died of Tuberculosis between January 2005 
and December 2006 Tarrant County
Years of Life Lost Years of Life-
Lived with 
Disability-acute
Years of Life-Lived 
with Disability - 
chronic (PIAT)
Disability Adjusted 
Life Years
Alive Dead Mean Sum Mean Sum Mean Sum Mean Sum
Race Caucasian 40 4 1.48 65.25 0.13 5.75 5.19 228.34 6.80 299.20
Hispanic 42 3 1.03 46.50 0.13 6.04 5.82 261.80 6.99 314.34
African-American 37 4 1.78 72.92 0.13 5.32 4.74 194.33 6.65 272.57
AAIO* 42 5 1.90 89.25 0.13 6.03 4.42 207.61 6.44 302.90
Age groups 0-4 7 0 0 0 0.14 1.01 7.65 53.55 7.79 54.56
5-14 0 0 0 0 0 0 0 0 0 0
15-29 27 0 0 0 0.14 3.88 6.63 179.04 6.77 182.92
30-44 49 4 1.81 96 0.13 7.04 5.74 304.55 7.69 407.45
45-59 49 5 1.72 93 0.13 7.04 4.99 269.5 6.84 369.54
60-69 13 6 4.15 78.92 0.13 1.87 2.82 53.58 7.07 134.37
70-79 13 0 0 0 0.14 1.87 2.11 27.47 2.26 29.34
80+ 3 1 1.5 6 0.11 0.43 1.1 4.4 2.71 10.83
Disease Site Pulmonary 141 14 1.69 261.67 0.13 20.13 5.6 868.59 7.42 1150.38
Extra-pulmonary 20 2 1.63 35.75 0.13 2.88 N/A* N/A* 1.76 38.63
Country of Birth USA born 78 10 2.27 199.67 0.13 11.07 4.65 409.05 7.04 619.79
Foreign-born 83 6 1.1 97.75 0.13 11.93 5.16 459.54 6.4 569.22
HIV status Negative 139 7 1.13 164.5 0.14 19.84 4.98 726.53 6.24 910.87
Positive 17 3 2.71 54.17 0.12 2.44 5.4 107.93 8.23 164.54
Unknown 5 6 7.16 78.75 0.07 0.72 3.1 34.13 10.33 113.6
Total 161 16 1.55 273.92 0.13 23.14 5.04 892.09 6.72 1189.01
*N/A Not Applicable; AAIO Africans, Asians, Indians & Other racial groups
Figure 1 Years of-life-lost (YLL), Years lived-with-disability-acute 
(YLD-Acute), Years lived-with-disability-chronic (YLD-Chronic) 
and Total Disability-Adjusted Life Years (DALY), for males and fe-
males. Total = YLL + YLD-Acute + YLD-Chronic.
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Figure 2 Racial Distribution of TB burden stratified by age groups 
for the 177 culture confirmed Tuberculosis patients seen be-
tween January 1, 2005 and December 31, 2006, Tarrant County, 
Texas.
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Discussion
Prior estimates of DALYs lost from TB included negative
health effects from YLD-acute, and years-of-life-lost, but
did not include YLD-chronic [2,14-16,20,22,23]. Using
methods recommend by the World Bank and used by
Murray et al in the Global Burden of Disease Study we
estimated the burden of TB including YLD-chronic. In
the urban area of Tarrant County, Texas, with reported
0.06/1000 incidence of TB [2], we calculated the burden
to be 0.37 DALYs lost /1000 population, per year. Prior
estimates of the TB burden in areas with similar TB inci-
dence, using the same methods but only measuring YLD-
acute and years-of-life-lost were 0.07 DALYs lost /1000
population, per year [3,16,20]. Our data from this study
show that disability is a major component of TB burden,
and that prior estimates of the DALYs lost from TB
accounted for only 25% of the total loss (table 2; figure 1).
Each occurrence of pulmonary TB illness results in
both YLD-acute and YLD-chronic from pulmonary
sequelae. We found that only 2% of the TB burden result-
ing was due to acute disease. This YLD-acute estimate
was similar to previously reported WHO estimates of TB
burden (approximately 0.1 DALY per case for areas with
very low adult and child mortality) [16,20].
Prior estimates of DAL Y s lost to TB do not consider
pulmonary impairment after tuberculosis. Pulmonary
impairment after tuberculosis is a common, life-long con-
dition [8-10], Vecino ME, Pasipanodya JG, Slocum PC,
Bae S, Munguia G, Miller TL, Drewyer G, Weis SE. 2010].
Evidence for chronic lung impairment in patients cured
of tuberculosis; Submitted]. Nearly 60% of patients have
measurable impairment after microbiological cure that
ranges from mild impairment to severe disability [8-10].
Exclusion of YLD-chronic from previous TB burden esti-
mates has led to recommendations that are incompletely
i n f o r m ed ,  n a m e l y  t h a t  w h e n  T B  i n c i d e n c e  i s  s t a b l e  o r
declining in a population, passive intervention is more
cost-effective than active case finding or treatment of
latent TB infection [4,33-35]. Such arguments support
reduced resource allocation for TB programs and that
policy action may have contributed to resurgence in U.S.
TB incidences seen in the early 1990s. Exclusion of PIAT
in estimates of TB burden undervalues the cost-effective-
n e s s  o f  T B  p r e v e n t i o n  a c t i v i t i e s  l e a d i n g  t o  i n a d e q u a t e
resources allocated to prevention [2].
Mortality due to TB is an important component of the
overall burden [1-5,14]. Years-of-life-lost accounted for
1.55 of the total 6.72 DALY lost per TB patient (table 2).
Previous estimates of the TB burden from low-incidence
areas reported 0.85 DALY lost from years-of-life-lost per
TB patient [16,20]. We believe the higher years-of-life-
lost found in this analysis was due to our study popula-
tion including only culture-confirmed TB. Clinical cases
of TB are less likely to suffer mortality and their inclusion
would have lowered years-of-life-lost [5]. The relation-
ship between illness-related mortality and disability is
often expressed as YLD: YLL ratio and has been used to
estimate DALYs lost from TB [19,21]. This ratio can be
used to estimate disability from an illness in a community
from mortality statistics. We found the YLD: YLL ratio
for TB to be 3.34. When this ratio was calculated for TB
without including YLD-chronic, the ratio was 0.08. Not
including YLD-chronic would have resulted in YLD: YLL
ratios that would have underestimated the TB burden.
Additionally these data demonstrated that in low-inci-
dence countries TB causes more DALYs lost from disabil-
ity than death.
The use of DALY to assess TB burden highlights previ-
ously recognized TB racial disparities that are less appar-
ent when either notification or mortality rates alone are
used [2]. Figure 3 illustrating the TB burden in the <5
years age group is consistent with recent TB transmission
to children among non-Caucasians. Substantial health
loss occurred to other racial groups at earlier ages than to
Caucasians in our cohort, a disparity that has social and
other implications, and indicates that practices to reduce
transmission or to prevent mortality may yield dispropor-
tionate benefits to these populations. Ranking burden of
disease by DALY loss gives information beyond the usual
disease descriptors of incidence, mortality, and age at ill-
ness. As an illustration of the added information from
Figure 4 Comparison of the effects of using Texas life-tables in-
stead of the Japanese life-tables on total tuberculosis burden.
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Figure 3 Sensitivity analysis: comparisons of the effects of vary-
ing the discount rates from 0 to 10%, on total TB Burden in DALY*. 
*Uniform age weights were applied throughout
0
100
200
300
400
500
600
700
800
0 - 4 5  - 14 15 - 29 30 - 44 45 - 59  60 - 69  70 - 79 80+
Age
DALY
0%
3%
7%
10%Pasipanodya et al. BMC Public Health 2010, 10:259
http://www.biomedcentral.com/1471-2458/10/259
Page 7 of 10
using DALY to calculate disease burden is aseptic menin-
gitis. Aseptic meningitis is far more common in Tarrant
County than TB. However mortality and long-term
sequelae are extremely rare. Therefore the disease burden
measured in DALY loss from aseptic meningitis is much
less than that due to tuberculosis. Without combining the
disease incidence, mortality, and impairment into a single
number, it is difficult to compare the respective disease
burdens from the two diseases.
There are emerging technologies for diagnosis and
treatment of TB that are close to clinical implementation.
These include the use of gamma interferon release assays
to diagnose LTBI, isoniazid and rifapentine to shorten
treatment of LTBI, and moxifloxacin containing regimes
to shorten treatment of active TB [36]. These data sug-
gests that the greatest health savings may be achieved
through strategies to prevent TB rather than strategies to
shorten its treatment.
This study gives insight into their potential effect on
h e a l t h  l os t  fr o m  T B .  I n t e rv e n t i o n s  t h a t  r e s u l t  i n  m o r e
persons completing LTBI therapy will prevent 6.72 DALY
p e r  c a s e  o f  T B  a v e r t e d .  I n  c o n t r a s t ,  i n t e r v e n t i o n s  f o r
shortening treatment of TB would result in little DALYs
saved. Reducing TB treatment duration by 50% would
have minimal effect on TB burden, as it would save <0.02
DALYs per patient. In addition shorter TB treatment
duration, assuming current costs of between US$5 and
US$350 per DALY gained, would not reduce the chronic
pulmonary impairment associated with TB [8-10,33]. If
preventing pulmonary impairment after tuberculosis is
considered, costs of current standard latent tuberculosis
infection therapy (daily isoniazid for 9 months) falls to
under US$2500 per DALY gained. The benefit of treating
latent tuberculosis infection becomes comparable to
those of treating non-infectious TB [33].
The use of discounting in economic health evaluations
and appropriate discount rates are controversial
[13,18,32,37-39]. We analyzed our results using the dis-
count rate recommend by the CDC and the U.S Preven-
tive Services Task Force (USPSTF) of 3% [13,14,32].
Irrespective of the discount rates used the present value
of DALYs lost to the cohort was significantly greater than
previous estimates. To improve the validity and precision
of the TB burden estimates, we tested disability weights
derived directly from the same TB-afflicted population in
sensitivity analysis [9]. Using these locally derived disabil-
ity weights did not change our conclusions. This analysis
indicates that the increased TB burden identified in this
study is independent of the discount rates or disability
weight used.
There are limitations to these estimates. We did not
adjust for co-morbidity including relapses, re-infections
drug-resistance, or acquired immuno-deficiency syn-
drome (AIDS). Additionally these results should be con-
sidered a conservative measure of tuberculosis burden, as
they do not include the contribution of clinical or extra
pulmonary tuberculosis or possible excess mortality after
cure. In addition, current DALY computation does not
weigh-in the effects of epidemiological parameters other
than age and gender. Pediatric and adolescent TB are
infrequent in Tarrant County, as in other low-incidence
areas; we were therefore unable to adequately test the
effects of age or the interaction of age and ethnicity in the
final analysis.
Even though the DALY is widely used and possibly one
of the best ways to quantify and estimate measurement of
morbidity and mortality for a given disease in a popula-
tion; there has been controversy over the appropriateness
of its use in the past especially when applied to certain
disadvantaged communities [30]. For example, DALY
assumptions are limited when applied to societies that
have clearly different life-tables from Japan [14,28,30].
We found a 14% difference in tuberculosis burden when
DALY was calculated using Texas life tables (figure 4). For
comparison of local burden disease, certainly use of local
life tables would account for this important difference.
One of the aims of this study was comparison of tubercu-
losis burden with or without inclusion of PIAT using
prior established methods. When these data are com-
bined PIAT contributed significantly to overall tubercu-
losis burden. Differential age weights would increase
importance of pediatric and adolescent mortality [14,21].
While the results are from a single geographic area we
included consecutive subjects within the defined period
to reduce selection bias and the population was heteroge-
neous. As a result we feel that despite these limitations
the results are representative of the TB burden in similar
populations.
Conclusions
Using the Global Burden of Disease Study methods we
demonstarate that pulmonary impairment after TB con-
tributes importantly to the TB burden, which is greater
t h a n  p r evi o u s l y  e s t i m a t ed .  T h e s e  d a t a  s u g g e s ts  t h a t  i n
low-incidence countries successful strategies to prevent
TB from developing may prevent more health burden
than previously recognized.
Appendix: Glossary of terms and acronyms used
Pulmonary Impairment After Tuberculosis (PIAT)
Pulmonary impairment after tuberculosis (PIAT) refers
to chronic pulmonary function loss that occurs in per-
sons who have achieved microbiologic cure of pulmonary
tuberculosis. Levels of impairment were determined in
previous studies via spirometry using American Medical
Association's Guide to Evaluations on Permanent Impair-
ment (fifth edition) [40]. Impairment was scaled none,
mild, moderate, or severe as follows: none (FVC > 80%Pasipanodya et al. BMC Public Health 2010, 10:259
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predicted and FEV1 > 80% predicted), mild (FVC 60-79%
predicted and FEV1 60-70% predicted), moderate (FVC
51-59% predicted, FEV1 41-59% predicted) and severe
(FVC < 50% predicted, FEV1 < 40% predicted) [8,40]. Dis-
ability associated with PIAT was evaluated by use of a val-
idated health related quality of life instrument, the St
George's respiratory questionnaire [9].
Disability adjusted life years (DALY)
DALY represents negative health effects of disease in a
population. One DALY represents the loss of one full year
of equivalent, complete health. DALYs were obtained
from the addition of two components: years of-life-lost
(YLL) and years lived-with-disability (YLD). Thus DALY
= YLL + YLD. T o be consistent with Global Burden of
Disease  S t udy  b y M u rra y et  al  we  used a  h ypo t het i ca l
norm of the maximum possible life expectancies for all
ages [13,14]. This makes DALY comparable across cul-
tures, countries, and regions. With this assumption Japa-
nese life expectancies at birth of 82.5 years for females
and 80.5 years for males were used [13,14,26-29]. DALY
measurement using this standard is based on the egalitar-
ian principle that allows death at the same age to contrib-
ute equally to burden of disease in different communities
across the globe.
Years of-life-lost (YLL)
YLL was calculated by defining a life expectancy and then
subtracting the actual age at death for each subject who
died.
Years lived-with-disability (YLD)
YLD are the non-fatal outcomes of TB. For this analysis
non-fatal, health impacts of TB were divided into years
lived-with-disability-acute and years lived-with-disabil-
ity-chronic. The measurements of these non-fatal out-
comes of tuberculosis were based on previous work that
directly measured pulmonary impairment and disability
after tuberculosis [8], [9], Vecino ME, Pasipanodya JG,
Slocum PC, Bae S, Munguia G, Miller TL, Drewyer G,
Weis SE. 2010. Evidence for chronic lung impairment in
patients cured of tuberculosis; Submitted].
Years lived-with-disability-acute (YLD-acute)
YLD-acute was defined as TB burden resulting from ill-
ness prior to completion of treatment and burden from
treatment-related side effects. The duration of YLD-acute
was assumed to be 6-months to be consistent with Global
Disease Study.
Years lived-with-disability-chronic (YLD-chronic)
YLD-chronic was defined as TB burden from disability
resulting from PIAT. The duration of this impairment
was assumed to be the time from completion of TB treat-
ment to the predicted life expectancy.
Discounting in this article refers to time preference for
consumption; when given a choice people generally value
healthy life in the present more than potential healthy life
in the future. Therefore potential life lost in the future is
valued less and is usually discounted at 3%.
Age weights
In DALY calculations, the age-weighting function speci-
fies the relative value of life lived at different ages. It is
used in the measurement of years-of-life-lost and years
lived-with-disability. Age weighting formula is Cxe-βx,
where x is the age corresponding to each year of life lost;
C = 0.1658; e is the natural logarithm which is a constant
approximately equal to 2.7183, β = 0.04.
This function can be can be adjusted by introducing a
constant (K) in order to modify weights, y = K Cxe-βx + (1-
K). K is the age weighting modulation factor, a parameter
that allows uniform (K = 0) or nonuniform (K = 1) age-
weighting to be used. When K = 0, years lost have equal
value. When K has a value higher than 0, years lost
acquire different values depending on age. The age weight
increases gradually from birth to the age of 25 and then
decreases. Age weights are controversial with strong
arguments for and against their inclusion in computation
of DALY. Note that YLL = 1/r(1-e-rl) in our base case
when K = 0.
Disability weights
The negative health impact of a medical condition can be
quantified over the duration of the condition using dis-
ability weighting. Disability weights have been calculated
in many ways. These include self-assessed with rating
scales (such as the visual analogue scales), magnitude
estimation (asking direct questions about the relative
value of time spent in each health state compared to
another) and trade-off methods (such as time trade-off,
willingness-to-pay and person trade-off) [16-20]. Disabil-
ity weights from PIAT in this study were also directly
derived from the St George's respiratory questionnaire
[9].
YLD: YLL ratio
The YLD: YLL ratio is years lived with disability (YLD) to
years of life lost (YLL). The YLD: YLL ratio can be used to
estimate disability from mortality of the disease in com-
munities where morbidity data is generally scarce. The
Global Burden of Disease study and the World Health
Organization have already established YLD: YLL ratios
for various diseases that have been stratified by age group
and geographical region. These established YLD: YLL
ratios have been used by some developing countries to
estimate TB DALYs [19].
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